At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from KEYNOTE-010, a phase 2/3 study of pembrolizumab, anti-PD-1 antibody, versus docetaxel for patients with PD-L1-positive non-small cell lung cancer (NSCLC) who had disease progression after platinum-containing systemic therapy.
KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression
4th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now